FDA Approval for Bayer's Menopause Drug
Bayer's Lynkuet, a non-hormonal therapeutic option, has received FDA approval for treating moderate-to-severe vasomotor symptoms of menopause.
The once-daily pill, elinzanetant, targets two receptors key to temperature regulation and will be marketed as a soft gel capsule taken before bedtime.
This new drug may offer an alternative to hormone therapies, which can increase the risk of cardiovascular complications, particularly for women with heart issues.
The approval of Lynkuet introduces competition to the market, including an Astellas Pharma product that has been available for two years.
The Bayer drug hits two central nervous system targets to treat moderate-to-severe menopause symptoms.
Author's summary: Bayer's Lynkuet approved for menopause symptoms.
More News
- iPhone 18 to Feature Simplified Camera Control Button: Report | iPhone in Canada
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Keurig Dr Pepper Shares Updates For Plan To Split Into 2 Companies
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- Why China’s “Taiwan Reunification” Shibboleth Is a Hoax
- The Angel Ball Honors Tina Knowles
- Travel-Ready Base Layers That Simplify Packing
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- Tomago Aluminium is more than just a smelter, it's a strategic asset
- AG Pam Bondi Launches Probe Into Biden's 'Autopen Pardons' After Blistering House Report